Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Zidovudine

Kuritzkes DR, Ribaudo HJ, Squires KE, et al. "Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s." J. Infect. Dis.. 2007;195(8):1169-76.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Parikh UM, Bacheler L, Koontz D, Mellors JW. "The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations." J. Virol.. 2006;80(10):4971-7.
Hammer SM, Ribaudo H, Bassett R, et al. "A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen." HIV Clin Trials. 2010;11(6):312-24.
Dubé MP, Parker RA, Mulligan K, et al. "Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384." Clin. Infect. Dis.. 2007;45(1):120-6.
Dubé MP, Komarow L, Mulligan K, et al. "Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384." J. Acquir. Immune Defic. Syndr.. 2007;45(5):508-14.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Moore JD, Acosta EP, Johnson VA, et al. "Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy." Antivir. Ther. (Lond.). 2007;12(6):981-6.
Aweeka FT, Rosenkranz SL, Segal Y, et al. "The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine." AIDS. 2006;20(14):1833-41.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Shulman NS, Kassaye SG, Winters MA, Johnston E, Katzenstein DA. "More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175." J. Infect. Dis.. 2007;196(2):328-9; author reply 329-30.
Tebas P, Zhang J, Hafner R, et al. "Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110." J. Antimicrob. Chemother.. 2009;63(5):998-1005.
Ribaudo HJ, Kuritzkes DR, Gulick RM. "A comparison of three initial antiretroviral AIDS regimens." N. Engl. J. Med.. 2007;357(10):1056-7.
Leger PD, Johnson DH, Robbins GK, et al. "Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384." J. Neurovirol.. 2014;20(3):304-8.
Brehm JH, Scott Y, Koontz DL, et al. "Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase." PLoS ONE. 2012;7(2):e31558.
Shikuma CM, Yang Y, Glesby MJ, et al. "Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095)." J. Acquir. Immune Defic. Syndr.. 2007;44(5):540-50.
Aweeka FT, Kang M, Yu J-Y, Lizak P, Alston B, Chung RT. "Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team." HIV Med.. 2007;8(5):288-94.

Young Adult

Macatangay BJC, Zheng L, Rinaldo CR, et al. "Comparison of immunologic assays for detecting immune responses in HIV immunotherapeutic studies: AIDS Clinical Trials Group Trial A5181." Clin. Vaccine Immunol.. 2010;17(9):1452-9.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. "Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study." J. Acquir. Immune Defic. Syndr.. 2010;55(1):117-27.
Weinberg A, Park J-G, Bosch R, et al. "Effect of Depot Medoxyprogesterone Acetate on Immune Functions and Inflammatory Markers of HIV-Infected Women." J. Acquir. Immune Defic. Syndr.. 2016;71(2):137-45.
Lockman S, Hughes MD, McIntyre J, et al. "Antiretroviral therapies in women after single-dose nevirapine exposure." N. Engl. J. Med.. 2010;363(16):1499-509.
Tenorio AR, Zheng Y, Bosch RJ, et al. "Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment." J. Infect. Dis.. 2014;210(8):1248-59.
Canter JA, Robbins GK, Selph D, et al. "African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy." J. Infect. Dis.. 2010;201(11):1703-7.
Jacobson JM, Zheng L, Wilson CC, et al. "The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection." J. Acquir. Immune Defic. Syndr.. 2016;71(2):163-71.
Shiboski CH, Chen H, Ghannoum MA, et al. "Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253." Int. J. Tuberc. Lung Dis.. 2014;18(6):682-8.
Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT. "Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population." PLoS ONE. 2015;10(6):e0129519.

Pages